A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 28,93 (+7,15%). A mediana é € 29,62 (+9,70%).
| Comprar |
9 |
| Manter |
13 |
| Vender |
2 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Doximity falls after downgrade by Freedom Capital
Doximity shares dropped 5.6% after Freedom Capital cut its rating from "buy" to "hold" while raising the price target from $24 to $27. The company reported Q1 results above expectations and raised its revenue outlook but lowered its EBITDA forecast to fund increased investments in AI development and computing power. Freedom Capital reduced its mid-point EBITDA estimate for 2027 from $329 million to $319 million and cited a balanced risk-reward profile for the downgrade; competition from Epic and OpenEvidence and tight pharma budgets remain risks, while AI search contracts are showing early positive momentum. » Mais em de.investing.com
Doximity CEO sells 8,505 shares to cover tax withholding after equity vesting
Doximity CEO Jeffrey Tangney sold 8,505 Class A shares on August 15 to satisfy tax withholding from vested awards, a non-discretionary transaction that reduced his direct stake by roughly 0.3% to 2,531,955 shares (about 1% ownership). The sale does not reflect a market judgment by Tangney and three other insiders had similar withholdings the same day. Company results show slowing top-line growth, margin pressure from rising AI compute costs, and a guidance lull as AI-related revenue recognition is expected later in the year, while the stock has fallen over 60% in the past year. » Mais em finance.yahoo.com
Doximity granted president 150,000 options as he sold small stake to cover taxes
Doximity president Steven L. Zatz sold 4,482 Class A shares in a non‑discretionary sell‑to‑cover to satisfy tax withholding after RSU vesting and retains 51,864 shares (~$1.29m at $24.80). The company granted Zatz 150,000 options on July 22 with a $20.49 strike that begin vesting in July 2027, tying future pay to stock appreciation. Doximity reported Q2 revenue of $156.6m (7% growth) and raised its full‑year range while AI compute costs lowered gross margin to 87.5% and adjusted EBITDA fell 6% to $74.8m; management says higher‑than‑expected AI usage should drive future revenue recognition. Investors should note the option grant links executive upside to stock performance as AI‑related costs and upcoming AI revenue recognition will affect margins and earnings. » Mais em finance.yahoo.com
Doximity CFO sells shares to cover taxes but keeps $12.1 million stake
Doximity CFO Matthew Sonefeldt reported a non-discretionary sale of 15,311 Class A shares on August 15 to satisfy tax obligations from equity vesting, leaving him with 486,238 shares valued at about $12.1 million. The filing does not signal a change in his view of the company. Doximity posted TTM revenue of $655.6 million and net income of $167.0 million, but guided to roughly 1% revenue growth for the September quarter as AI-related timing and higher AI compute costs pressured gross margin and adjusted EBITDA; the company also spent $91.6 million on share repurchases. Investors should note the transaction was routine vesting-related withholding and weigh it against the company's mixed near-term growth outlook and solid profitability. » Mais em finance.yahoo.com
Doximity says AI is generating high‑margin searches, shares jump
Doximity reported fiscal Q1 revenue of $156.6 million, up 7% year‑over‑year, while adjusted EBITDA fell 6% to $74.8 million as the company invests in AI. Management said its AI assistant outperformed peer models in an independent study, driving AI prompt volume up more than 25% quarter‑on‑quarter and AI Scribe users rising tenfold in July. CEO Jeff Tangney stated the company earns more than 10 times the cost per AI search today and expects AI costs to decline over time, signaling strong profit potential and prompting the stock rally. » Mais em finance.yahoo.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 154,09 mi | 7,30% |
| Ganho bruto | 131,71 mi | 1,62% |
| Ganho líquido | 30,66 mi | 42,02% |
| EBITDA | 48,27 mi | 25,86% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 5,05 bi |
Número de ações | 178,24 mi |
Máximo/mínimo de 52 semanas | € 47,25 - € 15,63 |
| Dividendos | Não |
Beta | 1,29 |
PER (PE Ratio) | 41,48 |
PEG (PEG Ratio) | -0,94 |
P/VC (PB Ratio) | 5,99 |
P/V (PS Ratio) | 8,38 |
Perfil da empresa
A Doximity, Inc. opera uma plataforma digital baseada na cloud para profissionais de saúde nos Estados Unidos. A plataforma da empresa disponibiliza aos seus membros ferramentas concebidas para profissionais de saúde, permitindo-lhes colaborar com os seus colegas, coordenar o acompanhamento dos doentes, realizar consultas virtuais, manter-se atualizados sobre as notícias e a investigação médicas mais recentes e gerir as suas carreiras. Serve principalmente fabricantes farmacêuticos e sistemas de saúde. A empresa era anteriormente conhecida como 3MD Communications, Inc. e mudou o nome para Doximity, Inc. em junho de 2010. A Doximity, Inc. foi constituída em 2010 e tem sede em São Francisco, Califórnia.
| Nome | DOXIMITY INC DL-,001 |
| CEO | Jeffrey A. Tangney |
| Sede | San Francisco,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Tecnologia de saúde |
| Entrada em bolsa | 02/01/2008 |
| Colaboradores | 880 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NYSE | DOCS |